RAM
BCAX

Readystate Asset Management’s Bicara Therapeutics BCAX Stock Holding History

Readystate Asset Management’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-270,200
Closed -$2.51M – 735
2025
Q2 		$2.51M Buy
+270,200
New +$3.22M 0.08% 140

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Readystate Asset Management's BCAX Position: Q3 2025 in Review

Readystate Asset Management sold out of Bicara Therapeutics (BCAX) in Q3 2025, closing a stake of 270,200 shares — an estimated $2.51M sold.

Readystate Asset Management first reported a position in BCAX in Q2 2025 and held it in 1 quarter. The position peaked at $2.51M in Q2 2025. 114 funds tracked by Wall St. Rank hold BCAX as of Q3 2025.

  • Readystate Asset Management reported no remaining Bicara Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Readystate Asset Management sold 270,200 Bicara Therapeutics shares in Q3 2025, an estimated $2.51M.
  • Readystate Asset Management first reported a position in Bicara Therapeutics in Q2 2025 and held it in 1 quarter.
  • Readystate Asset Management's Bicara Therapeutics position peaked at $2.51M in Q2 2025.
  • 114 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2025.

Based on Readystate Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.